Ignite Creation Date:
2024-05-06 @ 6:11 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05577442
Status:
UNKNOWN
Last Update Posted:
2022-10-19
First Post:
2022-10-09
Brief Title:
Trastuzumab Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR HER2 Advanced Breast Cancer
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-10-20
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-10-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-10-20
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-09
First Submit QC Date:
October 9 2022
Study First Post Date:
2022-10-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-17
Last Update Post Date:
2022-10-19
Last Update Post Date Type:
ACTUAL